
Longeveron LGVN
$ 0.85
0.07%
Annual report 2025
added 03-17-2026
Longeveron P/S Ratio 2011-2026 | LGVN
Annual P/S Ratio Longeveron
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.1 K | 6.02 K | 1.78 K | 50.1 | 108 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.1 K | 50.1 | 4.41 K |
P/S Ratio of other stocks in the Biotechnology industry
| Issuer | P/S Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.75 | - | 2.43 % | $ 254 M | ||
|
AgeX Therapeutics
AGE
|
0.099 | - | -10.17 % | $ 12.2 K | ||
|
BioNTech SE
BNTX
|
35.7 | $ 97.54 | -5.71 % | $ 27.2 B | ||
|
I-Mab
IMAB
|
94.1 | - | - | $ 866 M | ||
|
Burford Capital Limited
BUR
|
6.35 | $ 5.2 | 5.69 % | $ 820 M | ||
|
Midatech Pharma plc
MTP
|
137 | - | -18.52 % | $ 27.3 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.53 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
1.96 K | - | 2.54 % | $ 160 B | ||
|
Cerus Corporation
CERS
|
2.12 | $ 2.72 | 33.99 % | $ 518 M | ||
|
ACADIA Pharmaceuticals
ACAD
|
3.33 | $ 21.95 | -2.23 % | $ 3.64 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.39 K | - | -1.52 % | $ 24.7 M | ||
|
Ayala Pharmaceuticals
AYLA
|
11.2 | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
2.17 | - | - | $ 96.9 B | ||
|
Berkeley Lights
BLI
|
1.49 | - | -7.31 % | $ 87 M | ||
|
Calithera Biosciences
CALA
|
98.5 | - | -10.95 % | $ 876 K | ||
|
Advaxis
ADXS
|
144 | - | -9.65 % | $ 45.9 M | ||
|
CymaBay Therapeutics
CBAY
|
110 | - | - | $ 3.45 B | ||
|
ChemoCentryx
CCXI
|
0.0564 | - | - | $ 3.74 B | ||
|
Институт стволовых клеток человека
ISKJ
|
2.61 | - | - | - | ||
|
Cardiff Oncology
CRDF
|
196 | $ 1.71 | -1.16 % | $ 114 M | ||
|
Caladrius Biosciences
CLBS
|
3.58 | - | -16.75 % | $ 25.8 M | ||
|
Aeterna Zentaris
AEZS
|
7.87 | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
489 | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
65.5 | - | - | $ 26.5 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
7.34 | - | - | $ 2.18 B | ||
|
AIkido Pharma
AIKI
|
0.935 | - | 1.93 % | $ 17.4 M | ||
|
Editas Medicine
EDIT
|
5.08 | $ 2.9 | -3.33 % | $ 257 M | ||
|
Dynavax Technologies Corporation
DVAX
|
6.24 | - | - | $ 2.02 B | ||
|
Edesa Biotech
EDSA
|
158 | $ 17.59 | -3.75 % | $ 56.2 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
759 | $ 2.93 | -8.15 % | $ 4.82 M | ||
|
Eiger BioPharmaceuticals
EIGR
|
0.197 | - | -9.21 % | $ 2.55 M | ||
|
Eloxx Pharmaceuticals
ELOX
|
48.8 | - | -5.68 % | $ 8.28 M | ||
|
CureVac N.V.
CVAC
|
281 | - | - | $ 867 M | ||
|
Ampio Pharmaceuticals
AMPE
|
106 | - | -11.43 % | $ 502 K | ||
|
Applied Therapeutics
APLT
|
54.1 | - | - | $ 8.42 M | ||
|
Aptinyx
APTX
|
204 | - | -39.0 % | $ 4.57 M | ||
|
Evogene Ltd.
EVGN
|
71.3 | $ 0.81 | 3.33 % | $ 27.9 M | ||
|
Aravive
ARAV
|
6.61 | - | -13.39 % | $ 1.45 M | ||
|
Aridis Pharmaceuticals
ARDS
|
1.34 | - | 17.91 % | $ 11.1 M |